Rocket Pharmaceuticals Statistics
Total Valuation
RCKT has a market cap or net worth of $371.26 million. The enterprise value is $250.55 million.
| Market Cap | 371.26M |
| Enterprise Value | 250.55M |
Important Dates
The next estimated earnings date is Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RCKT has 109.19 million shares outstanding. The number of shares has increased by 12.83% in one year.
| Current Share Class | 109.19M |
| Shares Outstanding | 109.19M |
| Shares Change (YoY) | +12.83% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 3.63% |
| Owned by Institutions (%) | 73.37% |
| Float | 86.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 17.93 |
| PB Ratio | 1.57 |
| P/TBV Ratio | 2.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.10.
| Current Ratio | 6.12 |
| Quick Ratio | 5.90 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -112.39 |
Financial Efficiency
Return on equity (ROE) is -64.41% and return on invested capital (ROIC) is -37.96%.
| Return on Equity (ROE) | -64.41% |
| Return on Assets (ROA) | -35.14% |
| Return on Invested Capital (ROIC) | -37.96% |
| Return on Capital Employed (ROCE) | -81.49% |
| Weighted Average Cost of Capital (WACC) | 6.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 202 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +13.16% in the last 52 weeks. The beta is 0.45, so RCKT's price volatility has been lower than the market average.
| Beta (5Y) | 0.45 |
| 52-Week Price Change | +13.16% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 3.59 |
| Relative Strength Index (RSI) | 47.50 |
| Average Volume (20 Days) | 2,269,248 |
Short Selling Information
The latest short interest is 18.16 million, so 16.63% of the outstanding shares have been sold short.
| Short Interest | 18.16M |
| Short Previous Month | 21.90M |
| Short % of Shares Out | 16.63% |
| Short % of Float | 20.89% |
| Short Ratio (days to cover) | 5.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -212.64M |
| Pretax Income | -209.38M |
| Net Income | -209.38M |
| EBITDA | -202.46M |
| EBIT | -212.64M |
| Earnings Per Share (EPS) | -$1.88 |
Balance Sheet
The company has $144.38 million in cash and $24.76 million in debt, with a net cash position of $119.62 million or $1.10 per share.
| Cash & Cash Equivalents | 144.38M |
| Total Debt | 24.76M |
| Net Cash | 119.62M |
| Net Cash Per Share | $1.10 |
| Equity (Book Value) | 238.04M |
| Book Value Per Share | 2.18 |
| Working Capital | 125.36M |
Cash Flow
In the last 12 months, operating cash flow was -$179.62 million and capital expenditures -$169,000, giving a free cash flow of -$179.79 million.
| Operating Cash Flow | -179.62M |
| Capital Expenditures | -169,000 |
| Depreciation & Amortization | 10.18M |
| Net Borrowing | -1,000 |
| Free Cash Flow | -179.79M |
| FCF Per Share | -$1.65 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RCKT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -12.83% |
| Shareholder Yield | -12.83% |
| Earnings Yield | -56.56% |
| FCF Yield | -48.57% |
Analyst Forecast
The average price target for RCKT is $9.39, which is 176.18% higher than the current price. The consensus rating is "Buy".
| Price Target | $9.39 |
| Price Target Difference | 176.18% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |